Acalabrutinib plus rituximab followed by brexucabtagene autoleucel for frontline treatment of high-risk Mantle Cell Lymphoma: The window-3 clinical trial
Pilot trial demonstrates high response rates in high-risk mantle cell lymphoma patients following Acalabrutinib and CAR T therapy, suggesting improved management strategies.
Key Points
Overall response rate was 100% at day 30 post-CAR-T infusion, including 95% complete responses.
Treatment involved Acalabrutinib and Rituximab followed by brexucabtagene autoleucel in adult patients.
Median progression-free survival has not yet been reached with continuing follow-up in the analysis.
Study highlights the need for further investigation into managing cytokine release syndrome and other toxicities.